Introduction
============

HCC causes \~1 million mortalities worldwide annually and half of these mortalities occur in China ([@b1-ol-0-0-9079]). The areas of high HCC occurrence in China are concentrated in the southeast coastal areas, including Fujian ([@b2-ol-0-0-9079]). The complicated signal transduction pathways and underlying molecular pathogenesis involved in HCC are not fully understood. Several molecular markers have been proposed that may identify the metastatic potential and risk of recurrence of HCC; however, none have been approved for routine clinical use ([@b3-ol-0-0-9079]). Although pre-operative serum α-fetoprotein (AFP) is a commonly used diagnostic and prognostic marker for HCC, not all patients exhibit elevated AFP levels at the pre-operative stage ([@b4-ol-0-0-9079]). Therefore, other biomarkers or similar indicators are required that can be combined with AFP for prognostic and diagnostic use in HCC. Biological indicators associated with the recurrence of liver cancer subsequent to surgery are particularly significant in clinical practice ([@b5-ol-0-0-9079]). A number of tumor suppressors and oncogenes have been demonstrated to promote the transformed phenotype of cancer cells ([@b6-ol-0-0-9079]), along with splicing factors that have been previously confirmed as important participants in cancer development ([@b7-ol-0-0-9079]). Heterogeneous ribonucleoproteins (hnRNPs) area nuclear protein class that bind to nascent RNA transcripts, with a variety of roles in telomere biogenesis, DNA repair, cell signaling and the regulation of gene expression at the transcriptional and translational levels ([@b8-ol-0-0-9079]). hnRNPA1 belongs to a family of hnRNPs that function as splicing factors, and is involved in telomere biogenesis; telomeres of an hnRNPA1-deficient cell line were previously revealed to be shorter than those of a associated hnRNPA1-expressing cell line ([@b9-ol-0-0-9079]). In recent years, hnRNPA1 overexpression has been observed in various malignancies, and has been identified as a potential biomarker for early diagnosis, prognosis and monitoring during treatment of colorectal cancer ([@b10-ol-0-0-9079]--[@b13-ol-0-0-9079]). However, a previous study reported its prognostic value for surgically resected HCC (RHCC) ([@b14-ol-0-0-9079]), particularly in areas of high HCC occurrence in China. Studies have also demonstrated lymphatic infiltration caused by chronic inflammatory responses in the tumor and its surrounding tissues as a possible underlying cause of tumorigenesis ([@b15-ol-0-0-9079]); since the neutrophil to lymphocyte ratio (NLR) and the platelet to lymphocyte ratio (PLR) are the markers of immune status, they also reflect the inflammatory state and are associated with survival prognosis ([@b16-ol-0-0-9079],[@b17-ol-0-0-9079]). The correlation between inflammation indicators and hnRNPA1 in HCC is not yet clear. To address this, the present study investigated the significance of hnRNPA1 in two cohorts of patients with RHCC in Fujian, where HCC is common the clinicopathological data of all patients were collected, and hnRNPA1 expression was determined with reverse transcription-quantitative polymerase chain reaction (RT-qPCR), western blotting and immunohistochemistry (IHC). The correlations between hnRNPA1 expression and pre-operative serum AFP levels, NLR and PLR were also determined.

Materials and methods
=====================

### Patients and follow-up

Two independent cohorts of patients with HCC were enrolled for the study. This due to the different specimens we collected. Between June 2014 and February 2015, fresh liver cancer tissue samples were collected, which were used for RT-qPCR and western blot analyses. However, prior to March 2012, only collect paraffin-embedded liver cancer specimens, that were used for IHC were available. To determine the expression of hnRNPA1 in HCC tissues, 54 cancerous and pericancerous liver tissues (PCLT) were collected for RT-qPCR and western blot analyses (cohort 1). The samples were collected from patients with HCC who underwent curative resection at the Department of Hepatobiliary Surgery, Fuzhou General Hospital (Fujian, China), between June 2014 and February 2015. These patients were monitored following surgery until August 15, 2017. All specimens were collected immediately after resection, transported in liquid nitrogen and stored at −80°C. To evaluate the prognostic role of hnRNPA1 in HCC, tumor specimens for IHC analyses were obtained from 426 consecutive patients with HCC who underwent curative resection between January 2002 and March 2012 (cohort 2). These patients were evaluated from the day of surgical resection to the last day of follow-up (August 15, 2017), with a median follow-up time of 59 months (range, 2.0--128.0 months). Liver function and tumor differentiation were assessed by Child-Pugh classification ([@b18-ol-0-0-9079]) and the Edmondson grading system ([@b18-ol-0-0-9079]), respectively. Tumor stages were assessed according to the 2010 International Union Against Cancer Tumor-Node-Metastasis (TNM) classification system ([@b19-ol-0-0-9079]), and curative resection was defined as previously described ([@b14-ol-0-0-9079]). Overall survival (OS) was defined as the interval between surgery and mortality or between surgery and the last observation point. For surviving patients, the data were censored at the last follow-up. Relapse-free survival (RFS) was defined as the interval between the date of surgery and the date of diagnosis of any type of relapse (intra-hepatic recurrence or extrahepatic metastasis). The inclusion criteria included the following: ECOG score ([@b18-ol-0-0-9079]) of 0--1 prior to surgery, absence of ascites, hepatic encephalopathy and any distant metastasis, only one tumor lesion and Child-Pugh class A. Clinicopathological data of the patients with HCC ([Table I](#tI-ol-0-0-9079){ref-type="table"}) were collected from the hospital database medical records. Survival information was obtained from medical records, telephone interviews and the Social Security Death Index ([@b18-ol-0-0-9079]), and all pathological data were pathological characteristics originally assessed by pathologists.

### RT-qPCR

Total RNA was extracted from HCC tissues using TRIzol Reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer\'s protocols. cDNA was synthesized by HiScript reverse transcription kit (Vazyme Biotech Co., Ltd, Nanjing, China) and Real-time PCR SYBR Green kit (Vazyme Biotech Co., Ltd.) was used to prepare the protein according to the manufacturer\'s protocol. The negative control was used to replace the template with double distilled water and β-actin as control. The gene expression of hnRNPA1 and β-actin in from patient tissues was measured using One-Step RT-PCR Master mix (Thermo Fisher Scientific, Inc.). The primers used were: hnRNPA1 forward, 5′-TTTGACGACCATGACTCCGT-3′ and reverse, 5′-CACGACCACCACCAAAGTTT-3; and β-actin forward, 5′-AGCGAGCATCCCCCAAAGTT-3′ and reverse, 5′-GGGCACGAAGGCTCATCATT-3′. The reaction conditions were set to pre-denaturation at 95°C for 30 sec, PCR reaction at 94°C for 4 min, 94°C for 30 sec, 56°C for 30 sec, 72°C for 25 sec, dissolution curve conditions: 50°C 2 min, 95°C 10 min; 95°C 30 sec, 60°C 30 sec, 40 cycles. The expression of hnRNPA1 was measured relative to that of the β-actin standard and expressed as the 2^−∆∆Cq^ value ([@b20-ol-0-0-9079]).

### Western blotting

The newly resected HCC and PCLT tissues were weighed and protein was extracted by protein lysis buffer (RIPA; Beyotime Institute of Biotechnology Co., Ltd. Shanghai, China). The protein concentrations were measured by the bicinchoninic acid method and 40 µg protein was loaded into each lane on a 12% SDS-PAGE gel. Following electrophoresis, the protein bands were transferred to polyvinylidene fluoride (PVDF) membranes and blocked for 2 h at room temperature with PBS-0.05% Tween 20 containing 5% nonfat dry milk. The membranes were then incubated with the primary antibodies, rabbit anti-hnRNPA1 (ab177152; 1:4,000; Abcam, Cambridge, UK) and mouse anti-β-actin (BM0627; 1:200; Wuhan Boster Biological Technology, Ltd., Wuhan, China), overnight at 4°C. The membranes were washed with Tris-buffered saline with Tween-20 (1× PBS, 0.1% Tween-20) 3 times, and then incubated in HRP-conjugated goat anti-mouse (BA1051; 1:50,000; Wuhan Boster Biological Technology, Ltd, Wuhan, China) or goat anti-rabbit (BA1054; 1:50,000; Wuhan Boster Biological Engineering Co., Ltd, Wuhan, China) secondary antibodies in 1% nonfat dry milk in TBST for 1 h at room temperature. Membranes were washed 3 times in TBST and bound antibodies were detected using SuperSignal Chemiluminescent substrates (Thermo Fisher Scientific, Inc.) and chemiluminescence was detected on CL-XPosure Film (Thermo Fisher Scientific, Inc.). These data were analyzed via densitometry using Image-Pro plus v6.0 software (National Institutes of Health, Bethesda, MD, USA) and normalized to the expression of the internal control (β-actin).

### IHC

IHC methods published by Liu *et al* for a Her2 assay ([@b21-ol-0-0-9079]) were used to quantify hnRNPA1expression in 426 HCC tissue samples, with one modification: Anti-hnRNPA1 antibody (ab177152, 1:100; Abcam) replaced anti-HER-2 antibody. Pathological specimens from 426 HCC tissue samples were fixed in 4% neutral formaldehyde solution at room temperature for 24 h, embedded in paraffin and sliced into 4-mm sections. Paraffin was removed with xylene (15 min; Sinopharm Group Chemical Reagent Co., Ltd., Shanghai, China) and the sections were rehydrated through a graded alcohol series (anhydrous ethanol I, 5 min; anhydrous ethanol II, 5 min; 95% ethanol, 3 min; 90% ethanol, 3 min; 80% ethanol, 2 min; and 70% ethanol, 2 min) (Sinopharm Group Chemical Reagent Co., Ltd.). Antigen retrieval was performed by the microwave method. The sections were placed in a glass box filled with 10 mM citrate buffer (pH 6.0; Shanghai Yanjing Reagent Technology Co., Ltd., Shanghai, China), and the glass box was placed in a microwave oven (700 W; Midea KJ23B-AN; Midea Group Co., Foshan, China) and heated at 100°C for 10--15 min. After the repair solution is cooled to room temperature, the sections were removed and washed 3 times with PBS (pH 7.4) for 3 min each time. The sections were incubated overnight with the primary antibody anti-hnRNPA1 or TBS as negative control at 4°C for 30 min. This was followed by incubation with a horseradish peroxidase (HRP)-conjugated secondary antibody (KIT-5010; anti-rabbit/mouse IgG; 1:50,000; Fuzhou Maixin Biotech Co., Ltd., Fuzhou, China) at 37°C for 30 min. Chromagen detection was performed with 3,3′-diaminobenzidine and a substrate-chromogen (EnVision system; DAKO; Agilent Technologies, Inc., Santa Clara, CA, USA), followed by counter-staining with hematoxylin at room temperature for 1 min. In every section, five randomly selected visual fields of view were assessed by light microscopy at ×200 magnification (Olympus Corporation, Tokyo, Japan) to evaluate the expression on the expression of hnRNPA1. Positively stained cells were evaluated by two pathologists blinded to the patient data. Positive hnRNPA1 expression was localized to the nucleus of RHCC cells and was graded based on the number of stained cells. When \<10% cells were stained, the assessment was negative (−), while ≥10% staining was graded as positive (+). Among the positive samples, those with 10--25% positively stained cells were graded as +, those with 26--50% positive cells were graded as ++ and those with 51--75% positive cells were graded as +++. A grade of ++++ indicted \>75% positively stained cancer cells. RHCC tissue samples with -, + or ++ grading were classified as low hnRNPA1 expression, whereas those with +++ and ++++ grading were classified as high hnRNPA1 expression.

### Routine blood test

Blood samples were collected into EDTA tubes prior to surgical resection and routine blood tests were conducted to measure the pre-operative cell counts (total leukocytes, neutrophils, lymphocytes, platelets and erythrocytes). Hemoglobin counts were obtained from the patients\' medical records. Pre-operative NLR ([@b22-ol-0-0-9079]) and PLR ([@b23-ol-0-0-9079]) were measured, and their median values were found to be 5 and 91, respectively. The PLR and NLR values were used as a grouping threshold (high and low).

### Statistical analysis

All statistical analyses were performed using SPSS statistical software version 21.0 (IBM Corp., Armonk, NY, USA) and Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA). Student\'s unpaired t-test was used to compare the continuous variables data between groups. Associations between hnRNPA1 expression and patient clinicopathological characteristics were evaluated with the χ^2^ test. The correlation between hnRNPA1 expression and NLR/PLR was analyzed using Spearman\'s rank correlation test. The survival curves were plotted using Kaplan-Meier method and the prognostic significance of hnRNPA1 was analyzed using the log-rank test. Associations between hnRNPA1 expression, clinicopathological data and mortality risk were assessed using univariate regression analysis, and Cox multivariate regression analysis was used to determine independent prognostic factors. All statistical analyses were two-sided. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### hnRNPA1 is upregulated in HCC tissues

hnRNPA1 mRNA levels were measured in 54 paired HCC samples from cohort 1 by RT-qPCR. hnRNPA1 was revealed to be significantly overexpressed in tumor tissues compared with that in corresponding PCLT samples (P\<0.001; [Fig. 1A](#f1-ol-0-0-9079){ref-type="fig"}). Samples from patients with tumor recurrences (32/54) also revealed significantly higher levels of hnRNPA1mRNA than those from patients without recurrences (22/54; P\<0.001; [Fig. 1B](#f1-ol-0-0-9079){ref-type="fig"}). The expression of hnRNPA1in 54 HCC cases from cohort 1wasalso assessed at the protein level by western blotting, and significant overexpression of hnRNPA1 protein was confirmed in tumors compared with that in corresponding PCLTs (P\<0.001; [Fig. 1C and D](#f1-ol-0-0-9079){ref-type="fig"}).

Association between patient clinicopathological features and hnRNPA1 expression. Patient clinicopathological data (cohort 1 and 2; [Table I](#tI-ol-0-0-9079){ref-type="table"}) and the associations with differential hnRNPA1 expression (cohort 2; [Table II](#tII-ol-0-0-9079){ref-type="table"}) were assessed. Positive hnRNPA1 expression was confirmed in cancer cell nuclei with IHC in both high and low hnRNPA1 expression groups in cohort 2 ([Fig. 1E and F](#f1-ol-0-0-9079){ref-type="fig"}). High hnRNPA1 expression was significantly associated with elevated pre-operative blood AFP (P\<0.001), TNM stage (P=0.024), tumor size (\>5 cm) (P\<0.001), vascular invasion (P\<0.001), Edmonson grade (P\<0.001), NLR (P=0.005), PLR (P=0.002), survival (P\<0.001) and recurrence (P\<0.001). Age, sex, tumor location, hepatitis B virus (HBV) surface antigen and HBV DNA load (\>104 IU/ml) were not associated with hnRNPA1 expression ([Table II](#tII-ol-0-0-9079){ref-type="table"}).

### Analysis of hnRNPA1 expression during the observation period and RFS

Elevated hnRNPA1 expression (P\<0.001), age (P=0.006), TNM stage (P\<0.001), larger tumor size (P\<0.001), vascular invasion (P\<0.001), Edmonson grade (P=0.003), higher pre-operative serum AFP (P\<0.001) and advanced NLR (P=0.031) were associated with recurrence in patients with RHCC during the observation period, as determined by Kaplan-Meier survival and log-rank analyses ([Table III](#tIII-ol-0-0-9079){ref-type="table"}). Elevated hnRNPA1 expression was also significantly associated with shorter RFS during the same observation period; [Fig. 2A](#f2-ol-0-0-9079){ref-type="fig"} demonstrates the different RFS times (in months) in the high and low hnRNPA1 expression groups (P\<0.001). Univariate analyses confirmed that age (HR, 1.476; 95% CI, 1.107--1.968; P=0.008), TNM stage (HR, 1.978; 95% CI, 1.491--2.624; P\<0.001), tumor size (HR, 1.898; 95% CI, 1.438--2.506; P\<0.001), vascular invasion (HR, 6.850; 95% CI, 4.352--10.780; P\<0.001), Edmonson grade (HR, 0.563; 95% CI, 0.381--0.831; P=0.004), pre-operative blood AFP (HR, 1.742; 95% CI, 1.320--2.300; P=0.001), NLR (HR, 1.394; 95% CI, 1.023--1.899; P=0.035) and hnRNPA1 expression (HR, 2.295; 95% CI, 1.688--3.120; P\<0.001) were associated with RFS ([Table IV](#tIV-ol-0-0-9079){ref-type="table"}). Multivariate analysis confirmed that age (HR, 0.654; 95% CI, 0.488--0.877; P=0.005), vascular invasion (HR, 6.125; 95% CI, 3.835--9.870; P\<0.001) and hnRNPA1 expression (HR, 0.685; 95% CI, 0.506--0.928; P=0.015) were independent prognostic factors of RFS ([Table IV](#tIV-ol-0-0-9079){ref-type="table"}).

### Analysis of hnRNPA1 expression and OS during the observation period

Elevated hnRNPA1 expression (P\<0.001), Edmonson grade (P\<0.001), advanced TNM stage (P\<0.001), tumor size \>5 cm (P\<0.001), vascular invasion (P\<0.001), NLR (P\<0.001), PLR (P\<0.001) and higher pre-operative serum AFP (P\<0.001) were associated with worse OS for patients with RHCC ([Table III](#tIII-ol-0-0-9079){ref-type="table"}). Univariate analysis confirmed that TNM stage (HR, 2.357; 95% CI, 1.770--3.140; P\<0.001), tumor size (HR, 2.270; 95% CI, 1.690--3.050; P\<0.001), vascular invasion (HR, 7.542; 95% CI, 4.77--11.908; P\<0.001), Edmonson grade (HR, 0.296; 95% CI, 0.181--0.485; P\<0.001), pre-operative blood AFP (HR, 2.122; 95% CI, 1.594--2.827; P\<0.001), NLR (HR, 2.609; 95% CI, 1.775--3.835; P\<0.001), PLR (HR, 2.208; 95% CI, 1.658--2.941; P\<0.001) and hnRNPA1 expression (HR, 3.184; 95% CI, 2.244--4.518; P\<0.001) were associated with OS ([Table IV](#tIV-ol-0-0-9079){ref-type="table"}). Multivariate analysis confirmed that vascular invasion (HR, 6.118; 95% CI, 3.729--10.040; P\<0.001), pre-operative blood AFP (HR, 1.564; 95% CI, 1.151--2.126; P=0.004), NLR (HR, 1.758; 95% CI, 1.161--2.661; P=0.008) and hnRNPA1 expression (HR, 0.629; 95% CI, 0.454--0.871; P=0.005) were independent prognostic factors of OS ([Table IV](#tIV-ol-0-0-9079){ref-type="table"}). High hnRNPA1 expression was significantly associated with increased risk of mortality ([Table IV](#tIV-ol-0-0-9079){ref-type="table"}).

### Association between OS and hnRNPA1, NLR and PLR in patients with HCC during the observation period following curative resection

By the final follow-up, 48.1% (205/426) of the patients had suffered from recurrence and 44.6% (190/426) had succumbed in cohort 2. The 1-, 3- and 5-year OS rates in the whole cohort were 86.2, 66.7 and 58.9, respectively, and the 1-, 3- and 5-year recurrence rates were 29.6, 45.8 and 47.7%, respectively. Furthermore, it was revealed that patients with HCC with high hnRNPA1 expression had the poorest prognosis at 1, 3 and 5 years, with higher recurrence rates than in patients with low hnRNPA1 expression (51.4 vs. 20.4, 71.4 vs. 54.5 and 90.7 vs. 76.1%, respectively; P\<0.001; [Fig. 2A](#f2-ol-0-0-9079){ref-type="fig"}). Similarly, the 1-, 3- and 5-year overall survival rates of the patients with low expression of hnRNPA1 were significantly higher than the survival rates of the hnRNPA1 high group (94.6 vs. 80.7, 62.2 vs. 46.7 and 30.5 vs. 15.4%, respectively; P\<0.001; [Fig. 2B](#f2-ol-0-0-9079){ref-type="fig"}).

It was also revealed that patients with HCC with pre-operative NLR \>5 had the poorest prognosis at 1, 3 and 5 years, with higher cumulative recurrence rates than the patients with pre-operative NLR ≤5 (81.4 vs. 96.8, 48.5 vs. 62.4 and 19.9 vs. 24.8%, respectively; P\<0.001; [Fig. 2C](#f2-ol-0-0-9079){ref-type="fig"}). Similarly, the 1-, 3- and 5-year survival rates of the patients with pre-operative PLR \>91 were significantly lower than the survival rates of patients with pre-operative PLR ≤91 (73.8 vs. 92.5, 38.6 vs. 60.1 and 13.1 vs. 25.6%, respectively; P\<0.001; [Fig. 2D](#f2-ol-0-0-9079){ref-type="fig"}). The expression of hnRNPA1 was also positively correlated with NLR (Spearman\'s correlation; r=0.122, P=0.012) and PLR (Spearman\'s correlation; r=0.140, P=0.004).

Discussion
==========

HCC is a highly malignant type of cancer with poor survival rates. There are few HCC-specific biomarkers that are used in clinical practice, but the present study has revealed several potential prognostic indicators. In an attempt to identify a prognostic marker for HCC, hnRNPA1 expression was studied in tissue samples from patients with RHCC. hnRNPA1 is a nucleic acid binding protein that is distributed in various human tissues and organs. The selective splicing of hnRNPA1 is regulated throughout the human transcriptome and uses several mechanisms in conjunction with several splicing factors ([@b24-ol-0-0-9079]). It has been reported that knocking down hnRNPA1 and its downstream target pyruvate kinase muscle isozyme M2 (PKM2) can inhibit the growth of cancer cells ([@b25-ol-0-0-9079]). PKM2 promotes glucose metabolism and cancer cell growth through the let-7a/c-Myc/hnRNPA1 feedback loop mechanism ([@b26-ol-0-0-9079]). In addition, hnRNPA1 may prevent tumor cells from entering senescence by binding to telomeric DNA sequences ([@b27-ol-0-0-9079]).

The present study investigated the expression of hnRNPA1 in two cohorts of clinical HCC samples. In the 54 tumors samples from cohort 1, hnRNPA1 mRNA was highly expressed in the HCC tissues compared with that in the corresponding PCLTs. Samples from patients with recurrent HCC exhibited higher levels of hnRNPA1 than those without recurrence. In another independent cohort (cohort 2), similar results were obtained at the protein level. Another finding from the present study was the correlation between hnRNPA1 expression and a poor prognosis for HCC patients; overexpression of hnRNPA1 in HCC patients predicted lower OS rates and higher recurrence rates. Elevated hnRNPA1 expression was significantly associated with pre-operative blood AFP levels, TNM stage, tumor size, vascular invasion, Edmonson grade, NLR, PLR, survival and recurrence, but not with patient clinicopathological characteristics. These findings indicate an important role of hnRNPA1 gene in the recurrence of liver cancer. It is known that hnRNPA1 can activate the epidermal growth factor receptor/mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway in HCC cells to regulate the splicing of the insulin receptor transcript, as well as the Ras/MAPK/ERK pathway to regulate functional A-Raf gene splicing to stimulate tumor proliferation. Another study revealed that hnRNPA1/A2 overexpression can induce malignant transformation of immortalized hepatocytes and inhibit the apoptosis of HCC cells. If the inhibition of hnRNPA1/A2 expression can reduce *in vitro* growth and *in vivo* tumorigenesis of HCC cells, it is highly likely that it is required for HCC growth and development ([@b28-ol-0-0-9079]).

The present study also analyzed the effect of hnRNPA1 expression on tumor recurrence and metastasis in HCC patients, and revealed that the recurrence rate in the hnRNPA1-positive group was significantly higher, and that the survival rate was significantly lower compared with that in the hnRNPA1-negative group (P\<0.001), indicating that hnRNPA1 overexpression may present a potential risk of recurrence and metastasis. Multivariate analyses validated hnRNPA1 as a significant independent predictor for RFS (HR, 0.685; 95% CI, 0.506--0.928; P=0.015) and OS (HR, 0.629; 95% CI, 0.454--0.871; P=0.005). These observations were similar to those of previous reports on HCC ([@b14-ol-0-0-9079]) and other malignancies ([@b10-ol-0-0-9079]--[@b13-ol-0-0-9079]). Another study ([@b29-ol-0-0-9079]) reported a major role of hnRNPA1 in the majority of tumors, along with its association with metastasis in different cancer types. Furthermore, overexpression of hnRNPA1 promoted tumor invasion through regulating CD44v6, which indicated that hnRNPA1 may act as a marker for tumor aggressiveness and as a prognostic predictor in HCC ([@b14-ol-0-0-9079]).

Currently, the association between hnRNPA1 and the clinicopathological characteristics of HCC remains controversial. AFP is a well-known HCC biomarker used for monitoring treatment, and patients with elevated serum AFP frequently have a worse prognosis for OS ([@b30-ol-0-0-9079]). The risk of mortality increased significantly in patients with higher pre-operative serum AFP in the present study. Multivariate analyses validated that a pre-operative blood AFP level \>400 µg/l was an independent prognostic factor for RFS (HR, 1.350; 95% CI, 1.006--1.811; P=0.045) and OS (HR, 1.564; 95% CI, 1.151--2.126; P=0.004). The results of the present study also revealed a significant association between elevated hnRNPA1 expression and elevated pre-operative blood AFP. Therefore, the combination of hnRNPA1 expression and serum AFP presents a good biomarker for this specific population.

Elevated pre-operative AFP, tumor diameter \>5 cm and vascular invasion are three widely recognized factors affecting the prognosis of liver cancer patients, and have been incorporated into the guidelines for liver cancer diagnosis and treatment ([@b31-ol-0-0-9079]). Inflammation serves an important role in tumor formation, progression and invasion ([@b32-ol-0-0-9079]); the inflammatory cytokines released by immune cells can trigger oxidative damage and malignant transformation, and aggravate the inflammatory state, which enhances tumor growth, tissue invasion and metastasis ([@b15-ol-0-0-9079],[@b33-ol-0-0-9079]). Inflammatory factors released by tumor cells also stimulate tumorigenesis, tumor angiogenesis, invasion and metastasis ([@b34-ol-0-0-9079]). Neutrophils, an important mediator of inflammatory reactions, can further promote tumor growth and invasion by remodeling the extracellular matrix, which significantly inhibits lymphocyte-mediated tumor cell death. Platelet-reactive protein and other factors released by the platelets also encourage the proliferation of malignant tumor cells ([@b35-ol-0-0-9079]). Therefore, when the NLR and/or PLR increases, the immune system is weakened and cannot clear the tumor cells. Studies have shown that pre-operative elevated NLR and PLR are associated with poor prognosis in patients with liver cancer ([@b36-ol-0-0-9079],[@b37-ol-0-0-9079]). As biological indicators of systemic inflammation, NLR and PLR reflect the host immunity level. In the present study, pre-operative PLR level was not an independent risk factor for long-term survival, but patients with PLR \>91 had significantly lower long-term OS compared with patients with PLR ≤91. This is in agreement with a previous study, which associated pre-operative PLR ≥125 with higher tumor staging and aggressive tumor behavior, and showed it to be an independent prognostic factor for liver cancer recurrence following liver transplantation ([@b38-ol-0-0-9079]). Nevertheless, the heterogeneity among the selected subjects and PLR truncation methods may explain the differences between the aforementioned studies regarding the use of PLR as an independent risk factor for liver cancer patients. The mortality risk increased significantly in patients with higher pre-operative NLR, and multivariate analysis confirmed that higher pre-operative NLR had an unfavorable impact on OS (HR, 1.758; 95% CI, 1.161--2.661; P=0.008). hnRNPA1 expression level was correlated with NLR (r=0.122, P=0.012) and PLR (r=0.140, P=0.004). Taken together, the results of the present study point towards an association between hnRNPA1 expression and other biological markers of systemic inflammation, although the specific mechanism remains unclear.

Potential limitations of the present study include its retrospective nature, single-center sampling and the small sample size (480 patients in two independent cohorts). Therefore, to further validate these findings, a large-scale prospective study should be performed.

In conclusion, elevated hnRNPA1 may be an independent prognostic factor of increased mortality and recurrence risk. Clinical detection of hnRNPA1 levels could therefore be beneficial for the treatment and prognostic evaluation of HCC patients. In the present study, hnRNPA1 protein expression in HCC tissue was associated with AFP, NLR and PLR, and the combination of high hnRNPA1 and pre-operative serum AFP levels was a good biomarker for this specific population. There is also a possibility of a correlation between hnRNPA1 expression and biological markers of systemic inflammation. Future studies should focus on cytological and molecular investigations that may aid further understanding of the mechanism of hnRNPA1-mediated tumorigenesis/progression and unearth novel targets for the treatment of HCC.
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![hnRNPA1 is upregulated in HCC tissues. (A) Relative hnRNPA1 RNA levels between tumor tissues and PCLT (P\<0.001). (B) Relative hnRNPA1 RNA levels between patients with recurrence and no recurrence (P\<0.001). (C) Confirmation of hnRNPA1/β-actin protein expression in a representative case of HCC according to western blotting analysis. (D) The hnRNPA1/β-actin level between tumor tissues and corresponding PCLT samples from patients with recurrence and no recurrence (P\<0.001). (E) Representative image of high expression of hnRNPA1 in tumor tissue from a patient with HCC (×400 magnification). (F) Representative image of low expression of hnRNPA1 in tumor tissue from a patient with HCC (×400 magnification). hnRNPA1, heterogeneous nuclear ribonucleoprotein A1; HCC, hepatocellular carcinoma; PCLT, peri-cancerous liver tissues.](ol-16-03-3746-g00){#f1-ol-0-0-9079}
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###### 

Clinicopathological characteristics of patients with hepatocellular carcinoma in two cohorts.

                        Cohort 1 (n=54)   Cohort 2 (n=426)         
  --------------------- ----------------- ------------------ ----- ------
  Age, years                                                       
    ≤55                 29                53.7               174   40.8
    \>55                25                46.3               252   59.2
  Sex                                                              
    Male                45                83.3               378   88.7
    Female              9                 16.7               48    11.3
  Tumor location                                                   
    Left                15                27.8               101   23.7
    Right               39                72.2               325   76.3
  TNM stage                                                        
    I/II                37                68.5               292   68.5
    IIIa                17                31.5               134   31.5
  Tumor size, cm                                                   
    ≤5                  28                51.9               219   51.4
    \>5                 26                48.1               207   48.6
  Vascular invasion                                                
    Yes                 29                53.7               287   67.4
    No                  25                46.3               139   32.6
  Edmonson grade                                                   
    I                   43                79.6               343   80.5
    II--IV              11                20.4               83    19.5
  AFP, µg/l                                                        
    ≤400                32                59.3               267   62.7
    \>400               22                40.7               159   37.3
  HBsAg                                                            
    Negative            35                64.8               275   64.6
    Positive            19                35.2               151   35.4
  HBV DNA load, IU/ml                                              
    ≤104                30                55.6               224   52.6
    \>104               24                44.4               202   47.4
  NLR                                                              
    ≤5.0                18                33.3               125   29.3
    \>5.0               36                66.7               301   70.7
  PLR                                                              
    ≤91                 33                61.1               281   66.0
    \>91                21                38.9               145   34.0
  Survival                                                         
    Yes                 NA                NA                 236   55.4
    No                  NA                NA                 190   44.6
  Recurrence                                                       
    Yes                 32                59.3               205   48.1
    No                  22                40.7               221   51.9

TNM, Tumor-Node-Metastasis; AFP, α-fetoprotein; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; NA, not adopted; HBV, hepatitis B virus; HBsAg, HBV surface antigen; hnRNPA1, heterogeneous nuclear ribonucleoprotein A1.

###### 

Association between hnRNPA1 expression and clinicopathological characteristics in HCC (n=426; cohort 2).

                              hnRNPA1 expression level         
  --------------------- ----- -------------------------- ----- ---------
  Age, years                                                   
    ≤55                 174   92                         160   0.170
    \>55                252   75                         99    
  Sex                                                          
    Male                378   149                        229   0.867
    Female              48    18                         30    
  Tumor location                                               
    Left                101   41                         60    0.743
    Right               325   126                        199   
  TNM stage                                                    
    I/II                292   125                        167   0.024
    IIIa                134   42                         92    
  Tumor size, cm                                               
    ≤5                  219   97                         122   0.027
    \>5                 207   70                         137   
  Vascular invasion                                            
    Yes                 287   94                         193   \<0.001
    No                  139   73                         66    
  Edmonson grade                                               
    I                   343   114                        229   \<0.001
    II--IV              83    53                         30    
  AFP, µg/l                                                    
    ≤400                267   126                        141   \<0.001
    \>400               159   41                         118   
  HBsAg                                                        
    Negative            275   108                        167   0.968
    Positive            151   59                         92    
  HBV DNA load, IU/ml                                          
    ≤104                224   86                         138   0.719
    \>104               202   81                         121   
  NLR                                                          
    ≤5.0                125   62                         63    0.005
    \>5.0               301   105                        196   
  PLR                                                          
    ≤91                 281   125                        156   0.002
    \>91                145   42                         103   
  Survival                                                     
    Yes                 236   127                        109   \<0.001
    No                  190   40                         150   
  Recurrence                                                   
    Yes                 205   57                         148   \<0.001
    No                  221   110                        111   

TNM, Tumor-Node-Metastasis; AFP, α-fetoprotein; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; HBV, hepatitis B virus; HBsAg, HBV surface antigen; hnRNPA1, heterogeneous nuclear ribonucleoprotein A1.

###### 

Association between recurrence/survival and patient characteristics.

                        Survival   Recurrence                         
  --------------------- ---------- ------------ --------- ----- ----- ---------
  Age, years                                                          
    ≤55                 115        137          0.613     134   118   0.006
    \>55                75         99                     71    103   
  Sex                                                                 
    Male                174        204          0.135     185   193   0.292
    Female              16         32                     20    28    
  Tumor location                                                      
    Left                34         67           0.053     46    55    0.483
    Right               156        169                    159   166   
  TNM stage                                                           
    I/II                104        188          \<0.001   125   167   \<0.001
    IIIa                86         48                     80    54    
  Tumor size, cm                                                      
    ≤5                  70         149          \<0.001   88    131   \<0.001
    \>5                 120        87                     117   90    
  Vascular invasion                                                   
    Yes                 166        121          \<0.001   181   106   \<0.001
    No                  24         115                    24    115   
  Edmonson grade                                                      
    I                   172        171          \<0.001   175   168   0.003
    II--IV              18         65                     30    53    
  AFP, µg/l                                                           
    ≤400                99         168          \<0.001   115   152   \<0.001
    \>400               91         68                     90    69    
  HBsAg                                                               
    Negative            126        149          0.495     136   139   0.458
    Positive            64         87                     69    82    
  HBV DNA load, IU/ml                                                 
    ≤104                90         134          0.053     109   105   0.243
    \>104               100        102                    96    116   
  NLR                                                                 
    ≤5.0                31         94           \<0.001   55    70    0.031
    \>5.0               159        142                    150   151   
  PLR                                                                 
    ≤91                 103        178          \<0.001   134   147   0.095
    \>91                87         58                     71    74    
  hnRNPA1                                                             
    Low                 40         127          \<0.001   57    110   \<0.001
    High                109        150                    148   111   

OS and RFS were analyzed by Kaplan-Meier survival and log-rank analyses for all characteristics. P\<0.05 was considered to indicate a statistically significant difference. OS, overall survival; RFS, relapse-free survival; TNM, Tumor-Node-Metastasis; AFP, α-fetoprotein; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; HBV, hepatitis B virus; HBsAg, HBV surface antigen; hnRNPA1, heterogeneous nuclear ribonucleoprotein A1.

###### 

Univariate and multivariate Cox regression analysis of RFS and OS.

                                                                       RFS                     OS                                
  -------------------------------------------------------------------- ----------------------- --------- ----------------------- ---------
    Univariate analysis^[a](#tfn4-ol-0-0-9079){ref-type="table-fn"}^                                                             
    Age, years (≤55 vs. \>55)                                          1.476 (1.107--1.968)    0.008     0.928 (0.694--1.242)    0.615
    Sex (male vs female)                                               0.785 (0.495--1.245)    0.303     0.680 (0.407--1.134)    0.140
    Tumor location (left vs. right)                                    1.122 (0.808--1.558)    0.491     1.437 (0.991--2.084)    0.056
    TNM stage (I/II vs. IIIa)                                          1.978 (1.491--2.624)    \<0.001   2.357 (1.770--3.140)    \<0.001
    Tumor size, cm (≤5 vs. \>5)                                        1.898 (1.438--2.506)    \<0.001   2.270 (1.690--3.050)    \<0.001
    Vascular invasion (yes vs. no)                                     6.850 (4.352--10.780)   \<0.001   7.542 (4.77--11.908)    \<0.001
    Edmonson grade (I vs. II--IV)                                      0.563 (0.381--0.831)    0.004     0.296 (0.181--0.485)    \<0.001
    AFP, µg/l (≤400 vs. \>400)                                         1.742 (1.320--2.300)    \<0.001   2.122 (1.594--2.827)    \<0.001
    HBsAg (negative vs positive)                                       0.875 (0.654--1.170)    0.367     0.853 (0.631--1.154)    0.303
    HBV DNA load, IU/ml (≤104 vs. \>104)                               0.946 (0.719--1.244)    0.699     1.231 (0.926--1.637)    0.153
    NLR (≤5.0 vs. \>5.0)                                               1.394 (1.023--1.899)    0.035     2.609 (1.775--3.835)    \<0.001
    PLR (≤91 vs. \>91)                                                 1.271 (0.952--1.695)    0.103     2.208 (1.658--2.941)    \<0.001
    hnRNPA1 (low vs high)                                              2.295 (1.688--3.120)    \<0.001   3.184 (2.244--4.518)    \<0.001
  Multivariate analysisa                                                                                                         
    Age, years (≤55 vs. \>55)                                          0.654 (0.488--0.877)    0.005                             
    TNM stage (I/II vs. IIIa)                                          1.411 (0.950--2.094)    0.088     1.218 (0.815--1.819)    0.337
    Tumor size, cm (≤5 vs. \>5)                                        1.003 (0.681--1.478)    0.988     1.161 (0.763--1.766)    0.487
    Vascular invasion (yes vs. no)                                     6.125 (3.835--9.870)    \<0.001   6.118 (3.729--10.040)   \<0.001
    Edmonson grade (I vs. II--IV)                                      1.047 (0.688--1.592)    0.831     0.643 (0.380--1.086)    0.099
    AFP, µg/l (≤400 vs. \>400)                                         1.350 (1.006--1.811)    0.045     1.564 (1.151--2.126)    0.004
    NLR (≤5.0 vs. \>5.0)                                               1.020 (0.734--1.417)    0.907     1.758 (1.161--2.661)    0.008
    PLR (≤91 vs. \>91)                                                                                   1.343 (0.978--1.846)    0.069
    hnRNPA1 (low vs. high)                                             0.685 (0.506--0.928)    0.015     0.629 (0.454--0.871)    0.005

Cox proportional hazards regression. P\<0.05 was considered to indicate a statistically significant difference. RFS, relapse-free survival; OS, overall survival; AFP, α-fetoprotein; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; TNM, Tumor-Node-Metastasis; HR, hazard ratio; CI, confidential interval; HBV, hepatitis B virus; HBsAg, HBV surface antigen; hnRNPA1, heterogeneous nuclear ribonucleoprotein A1.
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